| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
|
Medicine details |
|
| Medicine name | temsirolimus (Torisel®) |
| Formulation | concentrate and diluent for solution for infusion |
| Reference number | 301 |
| Indication | Treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/01/2008 |
| NICE guidance | |